

**FORM PTO 1440**
(REV. 1-72)
U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

File No. 04-04

Serial No.
10/807,997**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Applicant(s):
Xu et al.Filing Date:
March 24, 2004

Group: 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
ZS	A1	5,723,299	03/03/98	Bell et al.	435	7.1	04/05/95
	A2	5,789,192	08/04/98	Moore et al.	435	69.1	08/23/93
	A3	5,843,725	12/01/98	Sledziewski et al.	435	69.7	06/07/95
	A4	5,945,511	08/31/99	Lok et al.	530	350	10/02/97
	A5	5,985,614	11/16/99	Rosen et al.	435	69.52	08/29/97
	A6	6,020,163	02/01/00	Conklin	435	69.1	08/06/98
	A7	6,486,301	11/26/02	Ebner et al.	530	351	01/15/99
	A8	6,576,743	06/10/03	Conklin et al.	530	351	05/17/99
	A9	6,610,286	08/26/03	Thompson et al.	424	85.2	12/22/00
	A10	2002042366	04/11/02	Thompson et al.	514	12	12/22/00

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A11	WO94/013801	06/23/94	WIPO			06/23/94
	A12	WO99/003982	01/28/99	WIPO			01/28/99
	A13	WO99/007740	02/18/99	WIPO			02/18/99
	A14	WO99/007848	02/18/99	WIPO			02/18/99
	A15	WO99/027103	06/03/99	WIPO			06/03/99

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

	A16	Abbas et al., "Cellular and Molecular Immunology", 4th Ed., pages 519-520, W.B. Saunders Company, 2000.
	A17	Albert et al., "Molecular Biology of the Cell," 3 rd Ed., pages 156-159, Garland Publishing, Inc., 1994.
	A18	Asadullah et al., Arch Dermatol 138:1189-1196, 2002.
	A19	Asadullah et al., Pharmacol Rev. 55(2):241-269, 2003.
	A20	Blumberg et al., Cell 104:9-19, 2001.
	A21	Cameron et al., "Cytokines and Chemokines in Autoimmune Disease," pages 8-32, Eurekah.com and Klawer Academic/Plenum Publishers, 2003.
	A22	Conti et al., Immunology Letters 88:171-174, 2003.
↓	A23	Cunningham et al., Science 244:1081-1085, 1989.

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (REV 2-32)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		File No: 04-04	Serial No. 10/807,997	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Applicant(s): Xu et al.		
				Filing Date: March 24, 2004	Group: 1614	
FOREIGN PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
ZS	A24	WO99/037772	07/29/99	WIPO		
	A25	WO99/046281	09/16/99	WIPO		
	A26	WO99/046379	09/16/99	WIPO		
	A27	WO99/061630	12/02/99	WIPO		
	A28	WO00/012708	03/09/00	WIPO		
	A29	WO00/039161	07/06/00	WIPO		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)						
	A30	Davis et al., <u>Cell</u> 87:1161-1169, 1996.				
	A31	De Groot-Kruseman et al., <u>J. Interferon & Cytokine Research</u> 22(Suppl. 1):S-97, Abstract P-2-1, 2002.				
	A32	Dumoutier et al., <u>Eur. Cytokine Netw</u> 13(2):5-15, 2002.				
	A33	Dumoutier et al., <u>J. Immunol.</u> 167:3545-3549, 2001.				
	A34	Dynan et al., <u>Nature</u> 316:774-778, 1985.				
	A35	Eickenscher et al., <u>TRENDS in Immunology</u> 23(2):89-96, 2002.				
	A36	George et al., "Macromolecular Sequencing & Synthesis," pages 127-149; Ch. 12, Alan R. Liss, Inc., 1988.				
	A37	Grüne, <u>Veterinary Immunol. And Immunopathol.</u> 88:1-12, 2002.				
	A38	Harlow et al., "Antibodies A Laboratory Manual," page 76, Ch. 5, Cold Springs Harbor Laboratory, 1988.				
	A39	He et al., <u>J. Interferon & Cytokine Research</u> 22(Suppl. 1):S-97, Abstract P-1-23, 2002.				
	A40	Henikoff et al., <u>Proc. Nat. Acad. Sci. USA</u> 89:10915-10919, 1992.				
	A41	Hosoi et al., <u>The 75th Annual Meeting, Department of Pharmacology, Kumamoto University</u> , Page 89P, Abstract P-112, 2002.				
V	A42	Kotenko, <u>Cytokine & Growth Factor Reviews</u> 13:223-240, 2002.				
Examiner				Date considered		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

FORM PTO 1449 (REV 2-32)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		File No. 04-04		Serial No. 10/807,997	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Applicant(s): Xu et al.			
				Filing Date: March 24, 2004		Group: 1614	
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
Z.S.	A43	WO00/042189	07/20/00	WIPO			
	A44	WO00/073457	12/07/00	WIPO			
	A45	WO00/078961	12/28/00	WIPO			
	A46	WO01/012672	02/22/01	WIPO			
	A47	WO01/046261	06/28/01	WIPO			
	A48	WO02/012345	02/14/02	WIPO			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)							
	A49	Kotenko et al., J. Biol. Chem. 276(4):2725-2732, 2001.					
	A50	Kotenko et al., Oncogene 19:2557-2565, 2000.					
	A51	Kunz et al., J. Interferon & Cytokine Research 22(Suppl. 1):S-97-S-98, Abstract P-2-3, 2002.					
	A52	Last et al., J. Investigative Dermatology 119(1):325, Abstract 707, 2002.					
	A53	Liu et al., Blood 100(11):189a-190a, Abstract #710, 2002.					
	A54	Liu et al., Journal of Immunology 152:1821-1829, 1994.					
	A55	Liu et al., Blood 102(9):3206-3209, 2003.					
	A56	Lutfalla et al., Genomics 16:366-373, 1993.					
	A57	Lutfalla et al., J. Mol. Evolution 41:338-344, 1995.					
	A58	Lillehoj et al., "Antibody Techniques," pages 291-305, Ch. 13, Academic Press, Inc., 1994.					
	A59	McKinnon et al., Drug News and Perspectives 9(7):389-398, 1996.					
	A60	Merck Manual 17 th Ed., pages 920-925.					
	A61	Mohler et al., FASB J. US Fed of American Soc. For Experimental Biology 6(4):A1123, 1992.					
	A62	Musso et al., J. Interferon & Cytokine Research 22(Suppl. 1):S-98, Abstract P-2-4, 2002.					
Examiner				Date considered			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO 1449
(REV 2-32)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

File No. 04-04

Serial No.
10/807,997

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant(s):
Xu et al.

Filing Date:
March 24, 2004

Group: 1614

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
ZS	A63	WO02/058724	08/01/02	WIPO			
	A64	WO02/070001	09/12/02	WIPO			
	A65	WO02/072607	09/19/02	WIPO			
	A66	WO03/039444	05/15/03	WIPO			
	A67	WO03/051384	06/26/03	WIPO			
	A68	WO04/085475	10/07/04	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

	A69	Ozaki et al., <i>J. Biol. Chem.</i> 277(33):29355-29358, 2002.
	A70	Parrish-Novak et al., <i>J. Biol. Chem.</i> 277(49):47517-47523, 2002.
	A71	Parrish-Novak et al., <i>J. Interferon & Cytokine Research</i> 22(Suppl. 1):S-46, Abstract W-1-5, 2002.
	A72	Pirhonen et al., <i>J. Interferon & Cytokine Research</i> 22(Suppl. 1): S-98, Abstract P-2-6, 2002.
	A73	Ramesh et al., <i>Cancer Gene Therapy</i> : S3, Abstract 008, 2002.
	A74	Rich et al., <i>Curr Biol.</i> 11(13):R531-R534, 2001.
	A75	Rich, <i>Expert Opin. Ther. Targets</i> 7(2):165-174, 2003.
	A76	Rohovsky et al., "Growth Factors and Wound Healing" pages 8-26, Ch. 2, Springer, 1997.
	A77	Roitt et al., "Immunology," 4 th Ed., pages 28.10-28.12, Mosby, 1996.
	A78	Rose-John, <i>Acta Biochimica Polonica</i> 50(3):603-611, 2003.
	A79	Salazar et al., <i>Eur. J. of Clin. Invest.</i> 31(12):1070-1077, 2001.
	A80	Slavin, <i>J. Immunol. Immunopharmacol</i> 17(1):25-29, 1997.
	A81	Stolina et al., <i>J. Interferon & Cytokine Research</i> 22(Suppl. 1):S-98-S-99, Abstract P-2-7, 2002.
✓	A82	Strengell et al., <i>J. Interferon & Cytokine Research</i> 22(Suppl. 1):S-99, Abstract P-2-8, 2002.

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (REV 2-32)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		File No. 04-04	Serial No. 10/807,997
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Applicant(s): Xu et al.	
				Filing Date: March 24, 2004	Group: 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)					
ZS	A83		Tachiiri et al., <u>Genes and Immunity</u> 4:153-159, 2003.		
	A84		Vandenbroeck et al., <u>J. Biol. Chem.</u> 277(28):25668-25676, 2002.		
	A85		Volk et al., <u>TRENDS in Immunology</u> 22(8):414-417, 2001.		
	A86		Walter, <u>Immunologic Res.</u> 26(1-3):303-308, 2002.		
	A87		Whitters et al., <u>J. Interferon & Cytokine Research</u> 22(Suppl. 1):S-99-S-100, Abstract P-2-11, 2002.		
	A88		Witek et al., <u>J. Interferon & Cytokine Research</u> 22(Suppl. 1):S-100, Abstract P-2-12, 2002.		
	A89		Wolk et al., <u>J. Immunol.</u> 168:5397-5402, 2002.		
	A90		Wuyts et al., <u>Eur J. Biochem.</u> 260:421-429, 1999.		
	A91		Xie et al., <u>J. Biol. Chem.</u> 275(40):31335-31339, 2000.		
	A92		Xu et al., <u>Proc. Nat. Acad. Sci. USA</u> 98(17):9511-9516, 2001.		
	A93		EST from Incyte Pharmaceuticals Inc., INC1429789, 1996.		
	A94		EST from Incyte Pharmaceuticals Inc., INC1922140, 1996.		
	A95		EST from Incyte Pharmaceuticals Inc., INC1923851, 1996.		
	A96		EST from Incyte Pharmaceuticals Inc., INC2119350, 1996.		
	A97		EST from Incyte Pharmaceuticals Inc., INC2270605, 1996.		
	A98		EST from Incyte Pharmaceuticals Inc., INC2699058, 1997.		
	A99		EST from Incyte Pharmaceuticals Inc., INC2701079, 1997.		
	A100		EST from Incyte Pharmaceuticals Inc., INC2720417, 1997.		
▼	A101		EST from Incyte Pharmaceuticals Inc., INC2763478, 1997.		
Examiner				Date considered	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO 1449 (REV 2-32)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		File No. 04-04	Serial No. 10/807,997
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Applicant(s): Xu et al.	
				Filing Date: March 24, 2004	Group: 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)					
ZS	A102		EST from Incyte Pharmaceuticals Inc., INC3256488, 1997.		
	A103		EST from Incyte Pharmaceuticals Inc., INC3257185, 1997.		
	A104		EST from Incyte Pharmaceuticals Inc., INC3316826, 1997.		
	A105		EST from Incyte Pharmaceuticals Inc., INC3376533, 1997.		
	A106		EST from Incyte Pharmaceuticals Inc., INC357666, 1995.		
	A107		EST from Incyte Pharmaceuticals Inc., INC4304592, 1998.		
	A108		EST from Incyte Pharmaceuticals Inc., INC758088, 1996.		
	A109		EST from Incyte Pharmaceuticals Inc., INC819592, 1996.		
	A110		EST from Incyte Pharmaceuticals Inc., INC904360, 1996.		
	A111		EST from TIGR Tentative Human Consensus, THC174656, 1997.		
	A112		EST from TIGR Tentative Human Consensus, THC197949, 1997.		
	A113		EST from TIGR Tentative Human Consensus, THC215509, 1997.		
	A114		GenBank Accession No. AA018585, 1995.		
	A115		GenBank Accession No. AA018749, 1995.		
	A116		GenBank Accession No. AA035594, 1995.		
	A117		GenBank Accession No. AA132964, 1995.		
	A118		GenBank Accession No. AA134881, 1995.		
	A119		GenBank Accession No. AA135185, 1995.		
	A120		GenBank Accession No. AA135300, 1995.		
Examiner				Date considered	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO 1449 (REV 2-32)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		File No. 04-04	Serial No. 10/807,997
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Applicant(s): Xu et al.	
				Filing Date: March 24, 2004	Group: 1614
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)					
ZS	A121		GenBank Accession No. AA299011, 1995.		
	A122		GenBank Accession No. AA412292, 1997.		
	A123		GenBank Accession No. AA470014, 1997.		
	A124		GenBank Accession No. AA494556, 1997.		
	A125		GenBank Accession No. AA514541, 1997.		
	A126		GenBank Accession No. AA516435, 1997.		
	A127		GenBank Accession No. AA528216, 1997.		
	A128		GenBank Accession No. AA583432, 1997.		
	A129		GenBank Accession No. AA632915, 1997.		
	A130		GenBank Accession No. H17201, 1995.		
	A131		GenBank Accession No. H17978, 1995.		
	A132		GenBank Accession No. N62509, 1995.		
	A133		GenBank Accession No. N79409, 1995.		
	A134		GenBank Accession No. R14678, 1995.		
	A135		GenBank Accession No. R42401, 1995.		
	A136		GenBank Accession No. T70354, 1995.		
↓	A137		GenBank Accession No. T70439, 1995.		
Examiner /Zachary Skelding/			Date considered 12/05/2006		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					